Metabolites of 2-(R)-4-isobutylarylpropionamides and pharmaceutical compositions containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
2-(R)-4-异丁基芳基丙酰胺的代谢产物及含有此类化合物的制药组合物在抑制由白细胞介素-8(IL-8)与CXCR1和CXCR2膜受体相互作用引起的中性粒细胞(PMN白细胞)趋化激活方面具有用途。这些化合物用于预防和治疗源于该激活的病理状况。值得注意的是,这些代谢产物不具有环氧合酶抑制活性,并且在治疗依赖于中性粒细胞的病理状况,如
银屑病、溃疡性结肠炎、
黑色素瘤、慢性阻塞性肺病(
COPD)、大疱性类天疱疮、类风湿性关节炎、特发性纤维化、肾小球肾炎以及缺血再灌注所致的损伤的预防和治疗方面特别有用。